step semaglutide Dose-equivalence reference based on pivotal GLP-1/dual-agonist trials: SURMOUNT-1 (tirzepatide/Zepbound, 72 weeks) STEP-1 (subcutaneous semaglutide/Wegovy, 68 weeks) OASIS-4 (oral semaglutide/Wegovy, 64 weeks). For educational comparison only—these are How to Inject Semaglutide |

What to Expect in 2025 and Beyond Todays GLP-1s are just the beginning of a major future factor influencing American health: behavior-supporting medication is in a renaissance, and investment in new medications and new indications is soaring

Related Stories Eight-hour eating window sustains long-term weight loss Weight loss drugs may reduce binge eating disorder symptoms GLP-1 weight loss may reduce first-impression penalties in relationships and hiring Tirzepatide is a co-agonist of the GIP receptor and GLP-1R and demonstrates greater efficacy for weight loss and glucose lowering than selective GLP-1RAs, with a broadly similar adverse event profile

"It's something else, but it's something that aids in helping break down the sugar obviously my body doesn't do it right

The weight management sector has faced problems for years with its assertions regarding the benefits of supplementation